Avacta Annual General Meeting and Shareholder Event Detailed Agenda
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to provide a detailed agenda for the 2023 Annual General Meeting (“AGM”) of Shareholders and subsequent Shareholder Event. The AGM will be held on Wednesday, 28 June 2023 at 10.30 a.m. BST at The Royal Society of Medicine, 1 Wimpole Street, Westminster, London W1G 0AE (the “Venue”).
10:15 Arrivals with coffee and biscuits.
10:30 Formal AGM Business and Voting on Resolutions chaired by Eliot Forster.
11:00 Business Update and Q&A: CEO Alastair Smith.
12:00 Buffet Lunch and poster session with the opportunity to meet the Group’s Senior Leadership.
· AVA6000 Poster
· AVA3996 Poster
· Affimer Therapeutics Poster
· Affimer Diagnostics Poster
· Launch Diagnostics Stand
13:00 AVA6000 Review of Public Domain Clinical Data.
13:20 Diagnostics Division Strategy with Q&A: Alastair Smith.
13:40 Closing comments and final Q&A: Alastair Smith.
14:00 Event ends.
No new material information will be disclosed during the meeting.
The Business Update (11:00-12:00) will be simultaneously streamed live on the Investor Meet Company (“IMC”) platform. Investors who already follow Avacta on IMC will automatically be invited to join the live stream. Investors who do not have an IMC account can sign up for free at https://www.investormeetcompany.com/avacta-group-plc/register-investor and then click “Add to meet” Avacta Group in order to receive an invitation.
The Venue has a capacity of approximately 140 people. Shareholders who wish to attend the AGM in person are requested to register by emailing FTI Consulting at [email protected] by 10:30 a.m. BST on 27 June 2023.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned